Lilly's Retevmo shows 83% reduction in disease recurrence for early-stage RET fusion-positive lung cancer
Phase 3 LIBRETTO-432 results indicate an 83% reduction in the risk of disease recurrence or death with Retevmo as adjuvant therapy.
Indication
Clinical and regulatory intelligence for RET fusion-positive lung cancer with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.